Cited by 114Pharmaceutical Practices and Patient OutcomesSubstance Abuse Treatment and OutcomesSleep and related disorders

The DOI matches its Crossref record; 187 of the 189 references it cites were found in a registry or an index.

Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review

Open access

Abstract

BACKGROUND: Long-term sedative use is prevalent and associated with significant morbidity, including adverse events such as falls, cognitive impairment, and sedation. The development of dependence can pose significant challenges when discontinuation is attempted as withdrawal symptoms often develop. We conducted a scoping review to map and characterize the literature and determine opportunities for future research regarding deprescribing strategies for long-term benzodiazepine and Z-drug (zopiclone, zolpidem, and zaleplon) use in community-dwelling adults. METHODS: We searched PubMed, Cochrane Central Register of Controlled Trials, EMBASE, PsycINFO, CINAHL, TRIP, and JBI Ovid databases and conducted a grey literature search. Articles discussing methods for deprescribing benzodiazepines or Z-drugs in community-dwelling adults were selected. RESULTS: Following removal of duplicates, 2797 articles were reviewed for eligibility. Of these, 367 were retrieved for full-text assessment and 139 were subsequently included for review. Seventy-four (53%) articles were original research, predominantly randomized controlled trials (n = 52 [37%]), whereas 58 (42%) were narrative reviews and seven (5%) were guidelines. Amongst original studies, pharmacologic strategies were the most commonly studied intervention (n = 42 [57%]). Additional deprescribing strategies included psychological therapies (n = 10 [14%]), mixed interventions (n = 12 [16%]), and others (n = 10 [14%]). Behaviour change interventions were commonly combined and included enablement (n = 56 [76%]), education (n = 36 [47%]), and training (n = 29 [39%]). Gradual dose reduction was frequently a component of studies, reviews, and guidelines, but methods varied widely. CONCLUSIONS: Approaches proposed for deprescribing benzodiazepines and Z-drugs are numerous and heterogeneous. Current research in this area using methods such as randomized trials and meta-analyses may too narrowly encompass potential strategies available to target this phenomenon. Realist synthesis methods would be well suited to understand the mechanisms by which deprescribing interventions work and why they fail.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40360-015-0019-8

Cites

187 of 187 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 PRISMA flow diagram showing results of search and process of selecting articles for review
Fig. 1 PRISMA flow diagram showing results of search and process of selecting articles for reviewCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 189 references

Research works printed but not linked: 11

  1. Ballenger JC, Pecknold J, Rickels K, Sellers EM. Medication discontinuation in panic disorder. J Clin Psychiatry. 1993;54 Suppl 10:15–21.
  2. Bartholomew S. Benzodiazepine dependence in the elderly. J Am Acad Phys Assist. 1990;3:535–9.
  3. Choy Y. Managing side effects of anxiolytics. Primary Psychiatry. 2007;14:68–76.
  4. Benzodiazepines: good practice guidelines for clinicians. Department of Health and Children, Ireland. 2002. http://hdl.handle.net/10147/46748 . Accessed 19 Jan 2014.
  5. DuPont RL. Thinking about stopping treatment for panic disorder. J Clin Psychiatry. 1990;51:38–45.
  6. Huston PG. Moderating benzodiazepine use in the elderly. Can Fam Phys. 1992;38:2459–67.
  7. Jensen B. Benzodiazepine comparison chart. In: Jensen B, Regier L, editors. RxFiles Drug Comparison Charts. 9th ed. Saskatoon: Saskatoon Health Region; 2013. p. 101.
  8. Management options for improving sleep. National Prescribing Service. 2010. http://www.nps.org.au/publications/health-professional/prescribing-practice-review/2010/prescribing-practice-review-49 . Accessed 31 Mar 2014.
  9. Saul PA, Korlipara K, Presley P. A randomised, multicentre, double-blind, comparison of atenolol and placebo in the control of benzodiazepine withdrawal symptoms. Acta Ther. 1989;15:117–23.
  10. Sloan E. Medication and substance use: keeping insomnia treatment safe. Insomnia Rounds. 2013;2:1–6.
  11. Zee P, Wang-Weigand S, Roth T. Facilitation of zolpidem discontinuation using ramelteon in subjects with chronic insomnia. Am J Addict. 2011;20:380–1.

Cited by

Sorted by citations

See all 114

Metadata

Authors
Pollmann, A. S., Murphy, A. L., Bergman, J. C., & Gardner, D. M.
Affiliations
Dalhousie University (CA)
Corresponding author
Pollmann, André S.
Venue
BMC Pharmacology and Toxicology
Published
2015-07-04
Volume
16
Issue
1
Pages
19-19
ISSN
2050-6511 (ISSN-L)
OpenAlex
W2170043108
Cited by
114
References
189
Citations by year
2026: 7 · 2025: 7 · 2024: 7 · 2023: 14 · 2022: 18 · 2021: 16 · 2020: 6 · 2019: 13 · 2018: 16 · 2017: 6 · 2016: 4
FWCI
4.34
Type
journal article
Language
en
Open access
Locations
  • BMC Pharmacology and Toxicology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Dalhousie University
  • College of Pharmacy, Dalhousie University
Topics
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
Keywords
deprescribing, benzodiazepines, Z-drugs, zopiclone, zolpidem, zaleplon, community-dwelling adults, benzodiazepine withdrawal, gradual dose reduction, behaviour change interventions, psychotherapy, realist synthesis
MeSH terms
Deprescriptions, Zolpidem, Acetamides, Benzodiazepines, Humans, Piperazines, Pyridines, Pyrimidines, Azabicyclo Compounds

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review